Combined with the previous clinical validation studies, this analytical validation demonstrates that the LDT version of the 12-gene molecular assay can be utilized for evaluating risk of distant recurrence in ER+/HER2- invasive breast cancer. The gene discussed is ERBB2; the disease is invasive breast carcinoma.